Patent Grant
8084420
The present invention generally relates to formulations combining rapid acting and long acting insulin formulations.
Intensive insulin therapy for diabetes involves providing a basal insulin, ideally present at a uniform level in the blood over a 24 hour period and a bolus or meal time (prandial) insulin to cover the added carbohydrate load from digestion concomitant with each meal.
In 1936, Hans Christian Hagedorn and B. Norman Jensen discovered that the effects of injected insulin could be prolonged by the addition of protamine obtained from the “milt” or semen of river trout. The insulin was added to the protamine and the solution was brought to pH 7 for injection. In 1946, Nordisk Company was able to form crystals of protamine and insulin and marketed it in 1950 as NPH, (Neutral Protamine Hagedorn, “NPH”) insulin. NPH insulin has the advantage that it can be mixed with an insulin that has a faster onset to compliment its longer lasting action. Eventually all animal insulins were replaced by human recombinant insulin.
Until very recently, and in many places today, basal insulin is usually provided by the administration of two daily doses of NPH insulin, separated by 12 hours. A patient eating three meals a day and using NPH insulin as the basal insulin requires five injections per day, one with each of three meals and two NPH insulin injections, one in the morning and the other at bedtime. To reduce the number of injections the patient must take, the morning dose of NPH insulin has been combined with a short acting insulin (recombinant human insulin) or a rapid acting insulin analog, such as lispro, A typical combination is a 70% NPH to 30% rapid acting insulin analog mixture. As a result, the patient can reduce the number of injections from five per day to four per day. See, e.g., Garber, Drugs 66(1):31-49 (2006).
Insulin glargine, which is currently sold under the trade name LANTUS® (Sanofi-Aventis Deutschland GmbH), is marketed as a “long-acting” insulin analog. LANTUS® can have up to 24 hour duration. LANTUS® typically starts to lower blood glucose about one hour after injection. J. Rosenstock and colleagues found that patients who took insulin glargine had a much lower risk of low blood glucose (hypoglycemia) than the patients who took NPH insulin. While LANTUS® is designed to cover the average patient's basal insulin needs over a 24 hour time period, the reality is that for many patients, it does not last long enough, causing them to be hyperglycemic, typically in the early morning hours. For some patients, LANTUS® is effective for only 12 hours, for others it is effective for 18 hours, and for still others it is effective for 24 hours. In an attempt to make LANTUS® last for 24 hours, the dose of LANTUS® is frequently increased. Unfortunately in these cases the risk of nocturnal hypoglycemia is also increased, which is a serious life-threatening condition that can lead to death.
Glargine cannot be mixed with other short or rapid acting insulins because the mixture causes glargine to precipitate prior to injection and administration of a precipitated insulin makes it virtually impossible to administer a known and reliable dose. The manufacturer of glargine warns users against mixing glargine with any other insulin.
It is therefore an object of the present invention to provide insulin formulations that can be used to reduce the number of daily injections to three.
It is another object of the present invention to provide a basal-bolus insulin formulation.
It is still another object of the present invention to provide a stable insulin formulation having immediate and long term release characteristics.
A combined fast or rapid acting-long acting insulin formulation has been developed wherein the pH of the fast or rapid acting insulin is adjusted so that both rapid and long acting insulins remain soluble when they are mixed together. Alternatively a very rapid acting insulin that has a pH at which the long acting insulin is soluble may be combined with the long acting insulin. Included in the preferred embodiment are any very rapid, rapid or fast acting insulin formulations combined with any intermediate, long or very long acting insulin at low pH. In another embodiment, any very rapid, rapid, or fast acting insulin can be combined with any intermediate, long or very long acting insulin at low pH, in the presence of a chelating agent and dissolution agent. In the most preferred embodiment, VIAJECT™ (a very rapid acting insulin formulation containing a zinc chelator and dissolution agent) is mixed with insulin glargine at pH 4 to produce a rapid initial spike in blood insulin concentration to cover the carbohydrates being absorbed from digestion of a meal and continue with a sustained release of insulin to produce a basal blood insulin level.
LANTUS® may be mixed with VIAJECT™, allowing a reduction in the number of daily insulin injections from 4 to 3. The compatibility of these formulations is due, in part, to the similarity in pH. When LANTUS® is combined with VIAJECT™, there is a change in the duration and magnitude of the glucose lowering effect of the long acting insulin analog. As disclosed herein, 7 out of 8 patients that have been followed for a 24 hour period of time showed a shorter duration of LANTUS® action when given as a single injection, compared to the identical dose given to the same patient in two separate injections administered at the same time. The duration and magnitude of the effect can also be varied by altering the ratio of the VIAJECT™ to LANTUS®. Thus by manipulating, i.e. shortening, the duration of the LANTUS®-containing formulation to 12 hours, the total number of injections that a patient would be required to take in a day, and achieve intensive glycemic control, can be reduced from 4 to 3 injections/day.
Experiments have been performed to demonstrate the importance of the addition of specific acids such as aspartic acid, glutamic acid, maleic, fumaric, or succinic acid to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the dimeric/monomeric form of insulin. These are added in addition to a chelator, preferably ethylenediaminetetraacetic acid (EDTA). Acids were selected based on their molecular size and structure to optimize association with hydrogen bonding sites on the insulin surface, effectively masking charged amino acid residues (see
As used herein, “insulin” refers to human or non-human, recombinant, purified or synthetic insulin or insulin analogues, unless otherwise specified.
As used herein, “human insulin” is the human peptide hormone secreted by the pancreas, whether isolated from a natural source or made by genetically altered microorganisms. As used herein, “non-human insulin” is from an animal source such as pig or cow.
As used herein, an “insulin analogue” is an altered insulin, different from the insulin secreted by the pancreas, but still available to the body for performing the same action as natural insulin. Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics. Examples include insulin lispro, insulin glargine, insulin aspart, insulin glulisine, insulin detemir. The insulin can also be modified chemically, for example, by acetylation. As used herein, human insulin analogues are altered human insulin which is able to perform the same action as human insulin.
As used herein, a “chelator” or “chelating agent” refers to a chemical compound that has the ability to form one or more bonds to zinc ions. The bonds are typically ionic or coordination bonds. The chelator can be an inorganic or an organic compound. A “chelate complex” is a complex in which the metal ion is bound to two or more atoms of the chelating agent.
As used herein, “duration of action” refers to the time period following administration of an insulin-containing formulation to reestablish baseline glucose blood levels (i.e. 120 mg/dl) post nadir.
As used herein “nadir” refers to the lowest glucose blood levels achieved following administration to a patient of an insulin-containing formulation.
As used herein, a “solubilizing agent” is a compound that increases the solubility of materials in a solvent, for example, insulin in an aqueous solution. Examples of solubilizing agents include surfactants (TWEENS®); solvent, such as ethanol; micelle forming compounds, such as oxyethylene monostearate; and pH-modifying agents.
As used herein, a “dissolution agent” is an acid that, when added to insulin and EDTA, enhances the transport and absorption of insulin relative to HCl and EDTA at the same pH, as measured using the epithelial cell transwell plate assay described in the examples below. HCl is not a dissolution agent but may be a solubilizing agent. Citric acid is a dissolution agent when measured in this assay.
As used herein, an “excipient” is an inactive substance other than a chelator or dissolution agent, used as a carrier for the insulin or used to aid the process by which a product is manufactured. In such cases, the active substance is dissolved or mixed with an excipient.
The formulations are suitable for subcutaneous administration and include insulin, a chelator and a dissolution agent(s) and one or more other excipients, as required, to make a formulation suitable for subcutaneous administration. The formulation will typically contain VIAJECT™ and LANTUS® in a ratio of units of insulin in VIAJECT™: units of insulin in LANTUS® from 1:0.5 to 1:20, preferably ranging from 1:1 to 1:10.7. In a preferred embodiment, the formulation contains a ratio of units of insulin in VIAJECT™: units of insulin in LANTUS® of 1:1. This formulation typically has a duration of action of 12 hours.
By combining the ingredients in VIAJECT™ (citric acid, EDTA and insulin) in different proportions/ratios, in combination with LANTUS®, one can control the magnitude and duration of the glucose lowering effect in patients with diabetes.
The composition includes a fast, rapid or very rapid acting insulin and an intermediate or long acting insulin. The rapid acting insulin is provided at a low pH, at which the long acting insulin does not precipitate when mixed together, even over a wide range of ratios of rapid acting to long acting insulin.
There are several differing types of commercial insulin available for diabetes patients. These types of insulins vary according to (1) how long they take to reach the bloodstream and start reducing blood glucose levels; (2) how long the insulin operates at maximum strength; and (3) how long the insulin continues to have an effect on blood sugar.
Fast Acting Insulin
Fast acting insulins are intended to respond to the glucose derived from ingestion of carbohydrates during a meal. Fast acting insulins start to work within one to 20 minutes, peaking about one hour later and lasting from three to five hours. Fast acting insulin takes about two hours to fully absorb into the systemic circulation. Fast acting insulins include regular recombinant human insulin (such as Humulin®, marketed by Eli Lilly®, and Novalin®, marketed by NovoNordisk®) which are administered in an isotonic solution at pH 7. Bovine and porcine insulins, which differ in several amino acids to human insulin, but are bioactive in humans, are also fast acting insulins.
Rapid Acting Insulin.
Some diabetes patients use rapid-acting insulin at mealtimes, and long-acting insulin for ‘background’ continuous insulin. This group includes insulins that have been modified or have altered locations of amino acids in order to enhance their rate of absorption.
At present there are three types of rapid-acting commercial insulin analogs available: lispro insulin (Lysine-Proline insulin, sold by Eli Lilly® as HUMALOG®), glulisine insulin (sold by Sanofi-Aventis® as APIDRA®) and aspart insulin (sold by Novo Nordisk® as NOVOLOG®).
Very Rapid acting Insulin
Biodel has a proprietary insulin formulation of regular human insulin that is even more rapid than the rapid acting insulin analogs, VIAJECT™. This is a formulation combining regular human insulin with EDTA and citric acid, at a pH of 4.
Intermediate Acting Insulin
Intermediate-acting insulin has a longer lifespan than short-acting insulin but it is slower to start working and takes longer to reach its maximum strength. Intermediate-acting insulin usually starts working within 2-4 hours after injection, peaks somewhere between 4-14 hours and remains effective up to 24 hours. Types of intermediate-acting insulin include NPH (Neutral Protamine Hagedorn) and LENTE® (insulin zinc suspension) insulin. NPH insulin contains protamine which slows down the speed of absorption so that the insulin takes longer to reach the bloodstream but has a longer peak and lifespan. Intermediate acting insulins may be combined with rapid acting insulins at neutral pH, to reduce the total number of injections per day.
Long Acting Insulin
A long acting insulin is insulin glargine is marketed under the tradename LANTUS®. The extended duration of action of LANTUS® is normally induced by the ph elevation from 4 to 7 post subcutaneous injection. This changes the solubility of the insulin glargine, creating a microprecipitate. This microprecipitate slowly dissolves in the subcutaneous tissue, sustaining its glucose lowering effect for up to 24 hours.
LANTUS® (insulin glargine) is a recombinant human insulin analog that can have up to 24 hour duration. It differs from human insulin by having a glycine instead of asparagine at position 21 and two arginines added to the carboxy-terminus of the beta-chain.
LANTUS® consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS® (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 μg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 μg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 μg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS® has a pH of approximately 4 prior to injection.
The median time between injection and the end of the pharmacological effect is a maximum of 24 hours after the injection. The median time between injection and the end of pharmacological effect was 24 hours for insulin glargine and 14.5 hours for NPH human insulin
The package insert says not to mix LANTUS® with any other types of insulin, unlike most rapid acting and intermediate acting insulins, due to precipitation of the insulins on mixing.
In the case of insulin glargine, there is no precipitate formed on mixing with VIAJECT™ which also has a pH of 4, matching that of the insulin glargine. Ultimately, this combination provides very rapid acting insulin to carry the patient through a meal with less bolus insulin, since it is very rapidly absorbed and eliminated shortly after meal digestion, thereby reducing the chance of hypoglycemia and providing 24 hour long lasting basal insulin. This ultimately reduces the number of injections required per day from four to three.
The choice of dissolution agent and chelator, the concentration of both the dissolution agent and the chelator, and the pH that the formulation is adjusted to, all have a profound effect on the efficacy of the system. While many combinations have efficacy, the preferred embodiment is chosen for many reasons, including safety, stability, regulatory profile, and performance.
In the preferred embodiment, at least one of the formulation ingredients is selected to mask any charges on the active agent. This may facilitate the transmembrane transport of the insulin and thereby increase both the onset of action and bioavailability for the insulin. The ingredients are also selected to form compositions that dissolve rapidly in aqueous medium. Preferably the insulin is absorbed and transported to the plasma quickly, resulting in a rapid onset of action (preferably beginning within about 5 minutes following administration and peaking at about 15-30 minutes following administration).
The chelator, such as EDTA, chelates the zinc in the insulin, thereby removing the zinc from the insulin solution. This shifts the equilibrium toward the dimeric and monomeric form and retards reassembly into the hexameric state. Since these two forms exist in a concentration-driven equilibrium, as the monomers are absorbed, more monomers are created. Thus, as insulin monomers are absorbed, additional dimers dissemble to form more monomers. The monomeric form has a molecular weight that is less than one-sixth the molecular weight of the hexameric form, thereby markedly increasing both the speed and quantity of insulin absorbed. To the extent that the chelator (such as EDTA) and/or dissolution agent (such as citric acid) hydrogen bond with the insulin, it is believed that it masks the charge on the insulin, facilitating its transmembrane transport and thereby increasing both the onset of action and bioavailability for insulin.
The insulin can be recombinant or purified from a natural source. The insulin can be human or non-human. Human is preferred. In the most preferred embodiment, the insulin is human recombinant insulin. Recombinant human insulin is available from a number of sources. The insulin may also be an insulin analogue which may be based on the amino acid sequence of human insulin but having one or more amino acids differences, or a chemically modified insulin or insulin analog.
The dosages of the insulin depends on its bioavailability and the patient to be treated. The actual systemic dose delivered to an individual ranges from 3 to 100 IU. For insulin with only 2.5% bioavailability, an oral dose of 4000 IU will deliver a 100 IU systemically available dose. For insulin with a much greater bioavailability, such as 50% bioavailability, delivery of a 3 IU systemically available dose requires an oral dose of only 6 IU.
Dissolution Agents
Certain acids appear to mask charges on the insulin, enhancing uptake and transport. Those acids which are effective as dissolution agents include acetic acid, ascorbic acid, citric acid, glutamic, aspartic, succinic, fumaric, maleic, and adipic, relative to hydrochloric acid, as measured in the transwell assay described in the examples below. A preferred dissolution agent is citric acid. Hydrochloric acid may be used for pH adjustment, in combination with any of the formulations, but is not a dissolution agent.
The amount of dissolution agent in the formulation is effective at masking charges on the insulin, and enhancing uptake of the insulin compared to the insulin alone. Preferably the formulation is between 9.37×10−4 M to 9.37×102M citric acid.
Chelators
In the preferred embodiment, a zinc chelator is mixed with the insulin. The chelator may be ionic or non-ionic. Suitable chelators include ethylenediaminetetraacetic acid (EDTA), ethylene-bis(oxyethylene nitro) tetraacetic acid (EGTA), di-, tri-sodium citrate, chlorella, cilantro, 1,2-Diaminocyclohexanetetraacetic acid (CDTA), dimercaptosuccinic acid (DMSA). Hydrochloric acid is used in conjunction with TSC to adjust the pH, and in the process gives rise to the formation of citric acid, which is a dissolution agent.
In the preferred embodiment, the chelator is EDTA. It is known that the chelator captures the zinc from insulin, thereby favoring the dimeric form of the insulin over the hexameric form and facilitating absorption of the insulin by the tissues surrounding the site of administration. In addition, the chelator hydrogen may bond to the active agent, thereby aiding the charge masking of the active agent and facilitating transmembrane transport of the active agent.
The amount of the chelator in the formulation is effective to enhance uptake of the insulin compared to the insulin alone. In the preferred embodiment, the chelator is EDTA. Preferably the formulation is between 2.42×10−4 M to 9.68×10−2 M EDTA.
Formulations
The active compounds or pharmaceutically acceptable salts thereof may be administered in the form of a pharmaceutical composition wherein the active compound(s) is in admixture or mixture with one or more pharmaceutically acceptable carriers, excipients or diluents. In a preferred embodiment the insulin is administered by injection, preferably subcutaneously (s.c.). The formulation for injection will typically be suspended in sterile water, phosphate buffered saline, saline or glycerin.
Other suitable pharmaceutically acceptable carriers, excipients or diluents are known. For example, solubilizing agents include wetting agents such as polysorbates and poloxamers, non-ionic and ionic surfactants, food acids and bases (e.g. sodium bicarbonate), and alcohols, and buffering acids or salts for pH control.
Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions. A number of stabilizers may be used. Suitable stabilizers include polysaccharides, such as cellulose and cellulose derivatives, and simple alcohols, such as glycerol; bacteriostatic agents such as phenol, m-cresol and methylparaben; isotonic agents, such as sodium chloride, glycerol, and glucose; lecithins, such as example natural lecithins (e.g. egg yolk lecithin or soya bean lecithin) and synthetic or semisynthetic lecithins (e.g. dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine or distearoyl-phosphatidylcholine; phosphatidic acids; phosphatidylethanolamines; phosphatidylserines such as distearoyl-phosphatidylserine, dipalmitoylphosphatidylserine and diarachidoylphosphatidylserine; phosphatidylglycerols; phosphatidylinositols; cardiolipins; sphingomyelins; and synthetic detergents, such as dioctanoylphosphatidyl choline and polyethylene-polypropylene glycol).
Other pharmaceutically acceptable excipients, solubilizing agents or other agents may be added to the insulin in lyophilized or dried form immediately before use, but may be added prior to use.
Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Baston, Pa. (1975), and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y. (1980). Proper formulation is dependent upon the route of administration chosen.
In the preferred embodiment, the formulation suitable for subcutaneous administration is formed by mixing the clinically desired amount of VIAJECT™ with LANTUS®, in a ratio that is titered to a specific patient's insulin requirements. The clear solutions are mixed and then injected subcutaneously into the patient. Mixing may occur in a separate vessel or within the syringe.
Although insulin formulations may be administered in a variety of manners, the formulations described herein are designed from delivery by injection, preferably subcutaneously. Following administration, the dosage form dissolves quickly releasing the drug or forming small particles containing drug, optionally containing one or more excipients. The formulation is designed to be rapidly absorbed and transported to the plasma for systemic delivery.
When LANTUS® is administered together with VIAJECT™, there is a change in the duration and magnitude of the glucose lowering effect of the long acting insulin analog. The duration and magnitude of the effect can also be varied by altering the ratio of the VIAJECT™ to LANTUS®. In one embodiment, the ration of VIAJECT™ to LANTUS® is selected to shorten the duration to 12 hours. This allows the total number of injections that a patient would be required to take in a day, and achieve intensive glycemic control, to be reduced from 4 to 3 injections/day. Thus a diabetic patient could administer an insulin formulation containing a combination of a long acting insulin, such as LANTUS®, and a very rapid acting insulin, such as VIAJECT™ in the morning, such as prior to eating breakfast, and then administer a prandial insulin, such as VIAJECT™, prior to eating lunch, and then administer a an insulin formulation containing a combination of a long acting insulin, such as LANTUS®, and a very rapid acting insulin, such as VIAJECT™ in the evening, such as prior to eating dinner.
The present invention will be further understood by reference to the following non-limiting examples.
The purpose of this study was to demonstrate in vitro the effect of EDTA in the presence of citric acid on absorption of insulin through an epithelial cell multilayer.
Materials and Methods
Two saline solutions were mixed. The first contained 1 mg/ml insulin, 2 mg/ml EDTA and 2 mg/ml citric acid (“solution 1”). The second contained 1 mg/ml insulin and 2 mg/ml citric acid (“solution 2”). The control (no cells) contained EDTA, citric acid and insulin. Immortalized human epithelial cell line cultures (10) were seeded on transwell plates (20)
The amount of insulin removed from the lower chamber at each time point was added to the amount removed in the previous time point(s) to determine the cumulative amount of insulin recovered in the lower chamber. Cells were stained to check for viability before and after the experiment. There was no statistical difference in the cell viability for each of the plates.
Results
Solution 1, which contained EDTA, moved through the multilayer of epithelial cells more effectively than solution 2, which did not contain EDTA. Therefore, the effect of combining EDTA with citric acid is to promote the speed and amount of absorption.
Methods and Materials
Oral epithelial cells that have been seeded on transwell plates were used to determine the rate of absorption through the cell multilayer, as described in example 1. Insulin (1 mg/ml) was dissolved in either aspartic (0.2 mg/mL) or citric acid (2 mg/ml) and EDTA (2 mg/ml) was added to both. Insulin with citric acid (no EDTA) was used as a control. The pH of the solution was approximately 3.5 to 4, and physiological same was present to provide an isotonic environment for the cells (0.85% NaCl, sufficient to produce a range of 280-310 mOsm as measured by freezing point depression, Microsmette, Precision systems, Natick, Mass.). Samples were taken from the receiver chamber and assayed by ELISA (Linco Corp.) for human recombinant insulin (μU/mL).
Results
Insulin/citric acid absorption through the cell layers was enhanced by the addition of EDTA, as shown by Example 2. However, aspartic acid was even more potent at enhancing insulin transport in the presence of EDTA, as shown by
This study demonstrated that different polyacids in the presence of EDTA have varying effects on insulin absorption, possibly due to varying degrees of charge masking.
Materials and Methods
Transwell plates seeded with oral epithelial cells were used for these experiments. The effect of EDTA was monitored by the amount of insulin that came through the lower chamber of the transwell plate.
Oral epithelial cells were grown on transwell inserts for 2 weeks until multiple (4-5) cell layers had formed. Transport studies were conducted by adding the appropriate solution (all contained 1 mg/ml human insulin) to the donor well and removing samples from the receiver well after 10 minutes. Insulin amounts in the receiver wells were assayed using ELISA. Apparent Permeability was calculated using the formula:
Apparent Permeability=Q/A(C)t
where Q=total amount permeated during incubation time in μg, A=area of insert in cm2, C=initial concentration in donor well in g/cm3 and t-total time of experiment in sec.
EDTA concentration is 0.45 mg/mL in all cases and the acid concentrations are as follows: Citric acid 0.57 mg/ml, Glutamic acid 0.74 mg/mL, Adipic acid 0.47 mg/mL, Oxalic acid 0.32 mg/mL. The pH of the solutions was 3.6 in all cases.
Results
The purpose of this study was to observe effect of acids and EDTA in an in vivo model.
Materials and Methods
Samples
Insulin was incorporated into a gel consisting of PVA (0.5%), Carbopol (2.7%), CMC (0.005%) and PEG 400 (0.14%), glycerin (0.14%), and EDTA (0.005%) by blending with insulin/aspartic acid or insulin/HCl. The final concentration of insulin in insulin/aspartic acid gel was 0.7 and insulin concentration in insulin/HCl gel was 1.7 mg/g.
Rat Rectal Study
Rats were fasted overnight and were cleared of all fecal matter with a warm water enema. Then the gel formulation was inserted into the rectum and the rat's blood glucose was monitored over an 8 hour time period.
Results
The results are shown in
The purpose of this study was to look at timing of glucose response when insulin is injected with a polyacid or organic acid in conjunction with EDTA. To further demonstrate that the type of acid is important to the rapid action of the dissociated insulin, a comparison of citric acid to HCl, was performed in miniature diabetic swine.
Materials and Methods
Insulin (0.9 mg/mL) was prepared as a clear isotonic solution containing citric acid (1.8 mg/mL), EDTA (1.8 mg/mL), and m-cresol as a preservative, pH ˜4. The comparator was prepared in the same manner, substituting HCl (0.001N) for citric acid and adjusting the pH with NaOH to approximately 4.
Diabetic mini pigs were not fed on the day of the study and were dosed with 0.08 U/kg on three occasions with the HCl formulation. For comparison, the citric acid formulation was used on two occasions with this dose, and four other occasions at a higher dose of 0.125 U/kg. Blood was drawn for insulin and glucose determination over the 8 hour study period.
Results
The results shown in
The purpose of this study was to look at the duration and magnitude of effect on blood glucose when a long acting insulin, LANTUS®, was combined with VIAJECT™.
Methods and Materials
Blood glucose (“BG”) of 9 patients (5 males and 4 females; age 40±10 yrs, body mass index (“BMI”) 24.0±2.0 kg/m2) were stabilized by glucose clamps (target BG 120 mg/dl). Prior to dosing, the glucose infusion was turned off. Using a cross over design with random treatment order, the same patient specific dose of VIAJECT™ and LANTUS® was injected subcutaneously immediately before the meal. On one occasion, the doses were together in the same injection. On another occasion the identical dose of each insulin was administered separately, at the same time, in two injections. Blood glucose was continuously monitored for 8 hours and glucose infusion was re-initiated if BG was less than 60 mg/dl. Plasma insulin levels were determined throughout the study.
Results
The mean blood glucose data is shown in
As shown by the p-values in Table 1, the first three hours have a very similar profile, which is typical of the rapid action of VIAJECT™ after a meal. However, the AUC's for 0-480 are statistically different, indicating a different time-action profile was obtained when LANTUS® and VIAJECT™ were administered together compared when they were administered separately.
An additional nine (9) patients were run over a period of 24 hours. Blood glucose (“BG”) of 9 patients were stabilized by glucose clamps (target BG 120 mg/dl). Prior to dosing, the glucose infusion was turned off. Using a cross over design with random treatment order, the same patient specific dose of VIAJECT™ and LANTUS® was injected s.c. immediately before the meal. On one occasion, the doses were together in the same injection. On another occasion the identical dose of each insulin was administered separately (in two injections) at the same time. Blood glucose was continuously monitored for 8 hours and out to 24 hours at 30 minute intervals. Glucose infusion was re-initiated if BG was less than 60 mg/dl. Plasma insulin levels were determined throughout the study. Since two of the patients received incomplete doses during the study, their data was omitted from the data provided below.
The mean blood glucose levels (mg/dl) for seven of these patients are shown in
The time to reestablish baseline glucose blood levels (120 mg/dl) post nadir, also referred to as “duration of action”, was calculated for seven patients and statistically evaluated using a paired t-test. The data is provided for seven patients in Table 2 below.
As shown by the data in Table 2, the duration of LANTUS® is shortened when it is administered together with VIAJECT™, compared to when it is administered separately.
The glucose values for a single patient (Patient F) included in the study described above are shown in
Duration may be further shortened by manipulation of the amount of VIAJECT™ (citric acid, EDTA and insulin) added. VIAJECT™:LANTUS® ratios (based on units of insulin) as low as 1:1.2 and as high as 1:12 were studied. The time to reach the established baseline of 120 mg/dl was determined for seven patients, and the corresponding ratio of VIAJECT™ to LANTUS® is provided in Table 3.
A rank order correlation coefficient was calculated based on the data in Table 3, R=0.875, N=8, p<0.007. There is a statistically significant relationship between the VIAJECT™ to LANTUS® ratio and time to return to baseline (120 mg/dl), demonstrating that increasing the amount of VIAJECT™ (citric acid, EDTA and insulin) reduces the duration of glucose lowering effect seen without these ingredients.
By combining the ingredients in VIAJECT™ (citric acid, EDTA and insulin) in different proportions/ratios, in combination with LANTUS®, one can control the magnitude and duration of the glucose lowering effect in patients with diabetes.
This application claims priority to U.S. Ser. No. 60/990,814 entitled “Rapid Acting and Long Acting Insulin Combination Formulations” filed Nov. 28, 2007. This application is a continuation-in-part of U.S. Ser. No. 11/695,562 entitled “Rapid Acting and Long Acting Insulin Combination Formulations” filed Apr. 2, 2007, by Solomon S. Steiner and Roderike Pohl, which claims priority to U.S. Ser. No. 60/744,687 entitled “Rapid Acting and Long Acting Insulin Combination Formulations” filed Apr. 12, 2006 by Solomon S. Steiner and Roderike Pohl. This application is also a continuation-in-part of U.S. Ser. No. 11/537,335 entitled “Rapid Acting and Prolonged Acting Insulin Preparations” filed Sep. 29, 2006 by Solomon S. Steiner and Roderike Pohl, which claims priority to U.S. Ser. No. 60/721,698, filed on Sep. 29, 2005. The disclosures in the applications listed above are herein incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2143590 | Scott | Jan 1939 | A |
| 2626228 | Petersen | Jan 1953 | A |
| 2819999 | Schlichtkrull | Jan 1958 | A |
| 3649456 | De Benneville et al. | Mar 1972 | A |
| 3683635 | Campanelli | Aug 1972 | A |
| 3906950 | Cocozza | Sep 1975 | A |
| 3921637 | Bennie et al. | Nov 1975 | A |
| 4129560 | Zoltobrocki | Dec 1978 | A |
| 4153689 | Hirai | May 1979 | A |
| 4196196 | Tiholiz | Apr 1980 | A |
| 4211769 | Okada | Jul 1980 | A |
| 4272398 | Jaffe | Jun 1981 | A |
| 4294829 | Suzuki | Oct 1981 | A |
| 4343898 | Markussen | Aug 1982 | A |
| 4377482 | Rivier | Mar 1983 | A |
| 4459226 | Grimes | Jul 1984 | A |
| 4489159 | Markussen | Dec 1984 | A |
| 4511505 | Morihara | Apr 1985 | A |
| 4659696 | Hirai | Apr 1987 | A |
| 4861627 | Mathiowitz | Aug 1989 | A |
| 4866051 | Hunt | Sep 1989 | A |
| 4946828 | Markussen | Aug 1990 | A |
| 5006343 | Benson | Apr 1991 | A |
| 5042975 | Chien | Aug 1991 | A |
| 5145684 | Liversidge et al. | Sep 1992 | A |
| 5188837 | Domb | Feb 1993 | A |
| 5204108 | Illum | Apr 1993 | A |
| 5260306 | Boardman et al. | Nov 1993 | A |
| 5352461 | Feldstein et al. | Oct 1994 | A |
| 5354562 | Platz | Oct 1994 | A |
| 5364838 | Rubsamen | Nov 1994 | A |
| 5458135 | Patton et al. | Oct 1995 | A |
| 5474978 | Bakaysa | Dec 1995 | A |
| 5482927 | Maniar | Jan 1996 | A |
| 5484606 | Dhabhar et al. | Jan 1996 | A |
| 5492112 | Mecikalski et al. | Feb 1996 | A |
| 5503852 | Steiner et al. | Apr 1996 | A |
| 5514646 | Chance et al. | May 1996 | A |
| 5534488 | Hoffmann | Jul 1996 | A |
| 5547929 | Anderson, Jr. et al. | Aug 1996 | A |
| 5562909 | Allcock et al. | Oct 1996 | A |
| 5577497 | Mecikalski et al. | Nov 1996 | A |
| 5650486 | Felippis | Jul 1997 | A |
| 5653961 | McNally et al. | Aug 1997 | A |
| 5653987 | Modi et al. | Aug 1997 | A |
| 5658878 | Bäckström et al. | Aug 1997 | A |
| 5672359 | Digenis | Sep 1997 | A |
| 5693338 | Milstein | Dec 1997 | A |
| 5740794 | Smith et al. | Apr 1998 | A |
| 5747445 | Bäckström et al. | May 1998 | A |
| 5763396 | Weiner et al. | Jun 1998 | A |
| RE35862 | Steiner et al. | Jul 1998 | E |
| 5785049 | Smith et al. | Jul 1998 | A |
| 5785989 | Stanley et al. | Jul 1998 | A |
| 5807315 | Van Antwerp et al. | Sep 1998 | A |
| 5849322 | Ebert et al. | Dec 1998 | A |
| 5874064 | Edwards et al. | Feb 1999 | A |
| 5877174 | Ono et al. | Mar 1999 | A |
| 5888477 | Gonda et al. | Mar 1999 | A |
| 5898028 | Jensen | Apr 1999 | A |
| 5901703 | Ohki et al. | May 1999 | A |
| 5912011 | Makino et al. | Jun 1999 | A |
| 5929027 | Takama et al. | Jul 1999 | A |
| 5952008 | Bäckström et al. | Sep 1999 | A |
| 5976569 | Milstein | Nov 1999 | A |
| 5985309 | Edwards et al. | Nov 1999 | A |
| 5997848 | Patton et al. | Dec 1999 | A |
| 6051256 | Platz et al. | Apr 2000 | A |
| 6063910 | Debenedetti | May 2000 | A |
| 6071497 | Steiner et al. | Jun 2000 | A |
| 6099517 | Daugherty | Aug 2000 | A |
| 6132766 | Sankaram et al. | Oct 2000 | A |
| 6153613 | Ono et al. | Nov 2000 | A |
| RE37053 | Hanes et al. | Feb 2001 | E |
| 6248363 | Patel et al. | Jun 2001 | B1 |
| 6254854 | Edwards et al. | Jul 2001 | B1 |
| 6264981 | Zhang | Jul 2001 | B1 |
| 6294204 | Rossling et al. | Sep 2001 | B1 |
| 6310038 | Havelund | Oct 2001 | B1 |
| 6331318 | Milstein | Dec 2001 | B1 |
| 6395744 | Adams et al. | May 2002 | B1 |
| 6423344 | Platz et al. | Jul 2002 | B1 |
| 6428771 | Steiner et al. | Aug 2002 | B1 |
| 6432383 | Modi | Aug 2002 | B1 |
| 6436443 | Edwards et al. | Aug 2002 | B2 |
| 6440463 | Feldstein et al. | Aug 2002 | B1 |
| 6444226 | Steiner et al. | Sep 2002 | B1 |
| 6447753 | Edwards et al. | Sep 2002 | B2 |
| 6465425 | Tracy | Oct 2002 | B1 |
| 6503480 | Edwards et al. | Jan 2003 | B1 |
| 6518239 | Kuo et al. | Feb 2003 | B1 |
| 6582728 | Platz | Jun 2003 | B1 |
| 6592904 | Platz et al. | Jul 2003 | B2 |
| 6635283 | Edwards et al. | Oct 2003 | B2 |
| 6652885 | Steiner et al. | Nov 2003 | B2 |
| 6676931 | Dugger | Jan 2004 | B2 |
| 6685967 | Patton | Feb 2004 | B1 |
| 6737045 | Patton | May 2004 | B2 |
| 6949258 | Zhang | Sep 2005 | B2 |
| 6960561 | Boderke | Nov 2005 | B2 |
| 7030084 | Ekwuribe et al. | Apr 2006 | B2 |
| 7089934 | Staniforth et al. | Aug 2006 | B2 |
| 7192919 | Tzannis | Mar 2007 | B2 |
| 7279457 | Pohl et al. | Oct 2007 | B2 |
| 20010039260 | Havelund | Nov 2001 | A1 |
| 20010043934 | L'Italien et al. | Nov 2001 | A1 |
| 20020198140 | Havelund | Dec 2002 | A1 |
| 20030017211 | Steiner | Jan 2003 | A1 |
| 20030064097 | Patel et al. | Apr 2003 | A1 |
| 20030068378 | Chen et al. | Apr 2003 | A1 |
| 20030172924 | Staniforth et al. | Sep 2003 | A1 |
| 20030194420 | Holl et al. | Oct 2003 | A1 |
| 20040096403 | Steiner | May 2004 | A1 |
| 20040151774 | Pauletti et al. | Aug 2004 | A1 |
| 20040157928 | Kim et al. | Aug 2004 | A1 |
| 20040077528 | Steiner | Sep 2004 | A1 |
| 20040182387 | Steiner | Sep 2004 | A1 |
| 20040247628 | Lintz et al. | Dec 2004 | A1 |
| 20050080000 | Thurow et al. | Apr 2005 | A1 |
| 20050153874 | Cheatham | Jul 2005 | A1 |
| 20050203001 | Arbit | Sep 2005 | A1 |
| 20050214251 | Pohl et al. | Sep 2005 | A1 |
| 20060067891 | Modi | Mar 2006 | A1 |
| 20070134279 | Stern | Jun 2007 | A1 |
| 20070155654 | Langkjaer | Jul 2007 | A1 |
| 20070086952 | Steiner | Sep 2007 | A1 |
| 20070235365 | Pohl et al. | Oct 2007 | A1 |
| 20080039365 | Steiner et al. | Feb 2008 | A1 |
| 20080039368 | Steiner et al. | Feb 2008 | A1 |
| 20080085298 | Pohl et al. | Apr 2008 | A1 |
| 20080090753 | Pohl et al. | Apr 2008 | A1 |
| 20080096800 | Pohl et al. | Apr 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 2 136 704 | May 1995 | CA |
| 247684 | Jul 1987 | DE |
| 0 069 715 | Jan 1983 | EP |
| 0 122 036 | Oct 1984 | EP |
| 0 220 958 | May 1987 | EP |
| 0 237 507 | Sep 1987 | EP |
| 0 257 915 | Feb 1988 | EP |
| 0 360 340 | Mar 1990 | EP |
| 0 364 235 | Apr 1990 | EP |
| 0 606 486 | Dec 1993 | EP |
| 0748213 | Dec 1996 | EP |
| 1 114 644 | Jul 2001 | EP |
| 1 428 524 | Jun 2004 | EP |
| 96911738 | Jun 2004 | EP |
| 2 069 502 | Aug 1981 | GB |
| 2240337 | Jul 1991 | GB |
| 2149545 | Feb 1992 | JP |
| 63020301 | Jan 1998 | JP |
| WO 9013285 | Nov 1990 | WO |
| WO 9104011 | Apr 1991 | WO |
| WO 9108764 | Jun 1991 | WO |
| WO 9116882 | Nov 1991 | WO |
| WO 9204069 | Mar 1992 | WO |
| WO 9208509 | May 1992 | WO |
| WO 9302712 | Feb 1993 | WO |
| WO 9317728 | Sep 1993 | WO |
| WO 9318754 | Sep 1993 | WO |
| WO 9400291 | Jan 1994 | WO |
| WO 9500127 | Jan 1995 | WO |
| WO 9511666 | May 1995 | WO |
| WO 9531979 | Nov 1995 | WO |
| WO 9534294 | Dec 1995 | WO |
| WO 9610996 | Apr 1996 | WO |
| WO 9636314 | Nov 1996 | WO |
| WO 9636352 | Nov 1996 | WO |
| WO 9733531 | Sep 1997 | WO |
| WO 9749386 | Dec 1997 | WO |
| WO 9842367 | Oct 1998 | WO |
| WO 9842368 | Oct 1998 | WO |
| WO 9842749 | Oct 1998 | WO |
| WO 9952506 | Oct 1999 | WO |
| WO 0100654 | Jan 2001 | WO |
| WO 0107107 | Feb 2001 | WO |
| WO 0211676 | Feb 2002 | WO |
| WO 03057170 | Jul 2003 | WO |
| WO 03086345 | Oct 2003 | WO |
| WO 03094951 | Nov 2003 | WO |
| WO 03101395 | Dec 2003 | WO |
| WO 2004056314 | Aug 2004 | WO |
| WO 2004075919 | Sep 2004 | WO |
| WO 2004080401 | Sep 2004 | WO |
| WO 2005089722 | Sep 2005 | WO |
| WO 2006088473 | Aug 2006 | WO |
| WO 2007041481 | Apr 2007 | WO |
| WO 2007047948 | Apr 2007 | WO |
| WO 2007121256 | Oct 2007 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20090137455 A1 | May 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60990814 | Nov 2007 | US | |
| 60744687 | Apr 2006 | US | |
| 60721698 | Sep 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11695562 | Apr 2007 | US |
| Child | 12324717 | US | |
| Parent | 11537335 | Sep 2006 | US |
| Child | 11695562 | US |
